Etiology, susceptibility, and treatment of acute bacterial exacerbations of complicated chronic bronchitis in the primary care setting: Ciprofloxacin 750 mg BID versus clarithromycin 500 mg BID

Clinical Therapeutics

Volumn 20, Issue 5, 1998, Pages 885-900

  Anzueto, Antonio ^a   Niederman, Michael S ^b   Tillotson, Glenn S ^c  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b WINTHROP UNIVERSITY HOSPITAL   (United States)

^c BAYER CORPORATION   (United States)

Author keywords

Acute exacerbations of chronic bronchitis; Ciprofloxacin; Clarithromycin; Resistance; Superinfection

Indexed keywords

CIPROFLOXACIN; CLARITHROMYCIN;

ADULT; AGED; AIRWAY OBSTRUCTION; ARTICLE; BACTERIUM ISOLATION; CHRONIC BRONCHITIS; CLINICAL TRIAL; COLONY FORMING UNIT; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG SAFETY; ENTEROBACTER; FEMALE; GASTROINTESTINAL SYMPTOM; HAEMOPHILUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MORAXELLA; PENICILLIN RESISTANCE; PRIMARY MEDICAL CARE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0031728911     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(98)80071-4     Document Type: Article

References (29)

1. Enright PL, Kronmal RA, Higgins MW, et al. Prevalence and correlates of respiratory symptoms and disease in the elderly. Cardiovascular Health Study. Chest. 1994;106:827-834.
2. National Heart, Lung, and Blood Institute. Morbidity and mortality. In: 1996 Chartbook on Cardiovascular, Lung, and Blood Diseases. Bethesda, Maryland: National Institutes of Health; 1996:5-9, 49-53.
3. Higgins MW, Thom T. Incidence, prevalence, and mortality: Intra- and intercounty differences. In: Hensley MJ, Saunders NA, eds. Clinical Epidemiology of Chronic Obstructive Pulmonary Disease. New York: Marcel Dekker; 1990:23-43.
4. Petty TL. A new national strategy for COPD. J Respir Dis. 1997;18:365-369.
5. Saint S, Bent S, Vittinghoff E, Grady D. Antibiotics in chronic obstructive pulmonary disease exacerbations. A metaanalysis. JAMA. 1995;273:957-960.
6. Balter MS, Hyland RH, Low D, et al. Recommendations on the management of chronic bronchitis: A practical guide for Canadian physicians. Can Med Assoc J. 1994;10(Suppl):5-23.
7. Ball P. Epidemiology and treatment of chronic bronchitis and its exacerbations. Chest. 1995;108(Suppl):43S-52S.
8. Chodosh S. Bronchitis and asthma. In: Gorbach SL, Bartlett JG, Blacklow NR, eds. Infectious Diseases. Philadelphia: W.B. Saunders; 1992:476-485.
9. Leeper KV, Jones AM, Tillotson G. The changing bacterial etiology of chronic obstructive pulmonary disease (COPD). Presented at Chest 1997, 63rd Annual International Scientific Assembly of the American College of Chest Physicians; October 26-30, 1997; New Orleans, Louisiana. Abstract.
10. Doern GV, Brueggemann AB, Holley HP Jr, Rauch AM. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: Results of a 30-center national surveillance study. Antimicrob Agents Chemother. 1996;40: 1208-1213.
11. Doern GV, Brueggemann AB, Pierce G, et al. Prevalence of antimicrobial resistance among 723 outpatient clinical isolates of Moraxella catarrhalis in the United States in 1994 and 1995: Results of a 30-center national surveillance study. Antimicrob Agents Chemother. 1996;40:2884-2886.
12. Doern GV, Brueggemann AB, Pierce G, et al. Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 and 1995 and detection of beta-lactamase-positive strains resistant to amoxicillin-clavulanate: Results of a national multicenter surveillance study. Antimicrob Agents Chemother. 1997;41:292-297.
13. Flemingham D, Gruneberg RN, and the Alexander Project Group. A multicentre collaborative study of the antimicrobial susceptibility of community-acquired, lower respiratory tract pathogens 1992-1993: The Alexander Project. J Antimicrob Chemother. 1996;38(Suppl A):1-57.
14. Gruneberg RN, Felmingham D, and the Alexander Project Group. Results of the Alexander Project: A continuing, multicenter study of the antimicrobial susceptibility of community-acquired lower respiratory tract bacterial pathogens. Diagn Microbiol Infect Dis. 1996;25:169-181.
15. Chodosh S, McCarty J, Farkas S, et al. Randomized, double-blind study of CIP and cefuroxime axetil for treatment of acute bacterial exacerbations of chronic bronchitis. Clin Infect Dis. In press.
16. Chodosh S, Schreurs A, Siami G, et al. Efficacy of oral ciprofloxacin vs CLA for treatment of acute bacterial exacerbations of chronic bronchitis. Clin Infect Dis. In press.
17. Anzueto A, Niederman MS, Haverstock DC, Tillotson GS. Efficacy of ciprofloxacin and clarithromycin in acute bacterial exacerbations of complicated chronic bronchitis: Interim analysis. Clin Ther. 1997;19:989-1001.
18. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1995;152 (Suppl):S77-S121.
19. Anthonisen NR, Manfeda J, Warren CPW, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196-204.
20. Approved Standard: Performance Standards for Antimicrobial Disk Susceptibility Tests. 4th ed. M2-A5. Villanova, Pa: National Committee for Clinical Laboratory Standards; 1993.
21. Approved Standard: Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. 2nd ed. M7-A3. Villanova, Pa: National Committee for Clinical Laboratory Standards; 1993.
22. Ball P, Make BJ. Acute exacerbations of chronic bronchitis: An international comparison. Chest. 1998;113(Suppl 3):199S-204S.
23. Eller J, Ede A, Schaberg T, et al. Infective exacerbations of chronic bronchitis: Relation between bacteriologic etiology and lung function. Chest. 1998;113:1542-1548.
24. Chodosh S, Lakshminarayan S, Swarz H, Breisch S. Efficacy and safety of a 10-day course of 400 or 600 milligrams of grepafloxacin once daily for treatment of acute bacterial exacerbations of chronic bronchitis: Comparison with a 10-day course of 500 milligrams of ciprofloxacin twice daily. Antimicrob Agents Chemother. 1998;42:114-120.
25. Baigelman W, Chodosh S, Pizzuto D, Sadow T. Quantitative sputum gram stains in chronic bronchial disease. Lung. 1979; 156:265-270.
26. Thornsberry C, Ogilvie P, Kahn J, Mauriz Y. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. Diagn Microbiol Infect Dis. 1997;29:249-257.
27. Siafakas NM, Vermeire P, Pride NB, et al. ERS consensus statement: Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur Respir J. 1995;8:1398-1420.
28. Celli BR, Snider GL, Heffner J, et al. ATS statement standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1995;152(Suppl pt 2):S77-S120.
29. Jardim JR, Consenso Latinoamericano sobre infecciones en bronquitis crónica. Rev Panam Infectiol. 1997;1:7-19.